Crispr dna targeting enzymes and systems
US-2024101990-A1 · Mar 28, 2024 · US
Isolated populations of renal stem cells and methods of isolating and using same
US9808488B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9808488-B2 |
| Application number | US-201414479385-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 8, 2014 |
| Priority date | Feb 26, 2009 |
| Publication date | Nov 7, 2017 |
| Grant date | Nov 7, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Isolated populations of fetal renal stem cells and progenitor cells are provided. Also provided are methods of generating and using these isolated populations of cells.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating a renal damage in a subject in need thereof comprising administering to the subject a therapeutically effective amount of renal cells comprising at least 50% cells having a NCAM+ signature, thereby treating the renal damage in the subject. 2. The method of claim 1 , wherein said administering is to a damaged kidney of the subject. 3. The method of claim 1 , wherein said renal cells comprising at least 50% cells having a NCAM+ signature comprise a NCAM+/EpCAM+ signature. 4. The method of claim 1 , wherein said renal cells comprising at least 50% cells having a NCAM+ signature comprise a NCAM+/CD133+ signature. 5. The method of claim 1 , wherein said renal cells comprising at least 50% cells having a NCAM+ signature comprise a NCAM+/CD24+ signature. 6. The method of claim 1 , further comprising enriching for said renal cells comprising at least 50% cells having a NCAM+ signature by culturing fetal renal cells of a fetal renal tissue in a culture medium devoid of serum prior to said administering. 7. The method of claim 1 , wherein said renal cells are seeded on a scaffold. 8. The method of claim 1 , wherein said renal cells comprise at least 60% cells having a NCAM+ signature. 9. The method of claim 1 , wherein said renal cells comprise at least 70% cells having a NCAM+ signature.
Assignees
Inventors
Classifications
from renal cells, from cells of the urinary tract · CPC title
Kidney cells · CPC title
Wnt; Frizzeled · CPC title
- C12N5/0687Primary
Renal stem cells; Renal progenitors · CPC title
Anti-neoplasic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9808488B2 cover?
- Isolated populations of fetal renal stem cells and progenitor cells are provided. Also provided are methods of generating and using these isolated populations of cells.
- Who is the assignee on this patent?
- Tel Hashomer Medical Res Infrastructure & Services Ltd
- What technology area does this patent fall under?
- Primary CPC classification C12N5/0687. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Nov 07 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).